In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.

Dupuytren's disease (DD) is a benign, fibroproliferative disease of the palmar fascia, with excessive extracellular matrix (ECM) deposition and over-production of cytokines and growth factors, resulting in digital fixed flexion contractures limiting hand function and patient quality of life. Su...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Farhatullah Syed, Alexis N Thomas, Subir Singh, Venkatesh Kolluru, Susan G Emeigh Hart, Ardeshir Bayat
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/97f76caf62034bed873be8847ebc93aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:97f76caf62034bed873be8847ebc93aa
record_format	dspace
spelling	oai:doaj.org-article:97f76caf62034bed873be8847ebc93aa2021-11-18T07:26:49ZIn vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.1932-620310.1371/journal.pone.0031430https://doaj.org/article/97f76caf62034bed873be8847ebc93aa2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22384021/?tool=EBIhttps://doaj.org/toc/1932-6203Dupuytren's disease (DD) is a benign, fibroproliferative disease of the palmar fascia, with excessive extracellular matrix (ECM) deposition and over-production of cytokines and growth factors, resulting in digital fixed flexion contractures limiting hand function and patient quality of life. Surgical fasciectomy is the gold standard treatment but is invasive and has associated morbidity without limiting disease recurrence. Injectable Collagenase Clostridium histolyticum (CCH)--Xiaflex®--is a novel, nonsurgical option with clinically proven in vivo reduction of DD contractures but with limited in vitro data demonstrating its cellular and molecular effects. The aim of this study was to delineate the effects of CCH on primary fibroblasts isolated from DD and non-DD anatomical sites (using RTCA, LDH, WST-1, FACS, qRT-PCR, ELISA and In-Cell Quantitative Western Blotting) to compare the efficacy of varying concentrations of Xiaflex® against a reagent grade Collagenase, Collagenase A. Results demonstrated that DD nodule and cord fibroblasts had greater proliferation than those from fat and skin. Xiaflex® exposure resulted in dose- and time-dependent inhibition of cellular spreading, attachment and proliferation, with cellular recovery after enzyme removal. Unlike Collagenase A, Xiaflex® did not cause apoptosis. Collagen expression patterns were significantly (p<0.05) different in DD fibroblasts across anatomical sites - the highest levels of collagen I and III were detected in DD nodule, with DD cord and fat fibroblasts demonstrating a smaller increase in both collagen expression relative to DD skin. Xiaflex® significantly (p<0.05) down-regulated ECM components, cytokines and growth factors in a dose-dependent manner. An in vitro scratch wound assay model demonstrated that, at low concentrations, Xiaflex® enabled a faster fibroblast reparatory migration into the wound, whereas, at high concentrations, this process was significantly (p<0.05) inhibited. This is the first report elucidating potential mechanisms of action of Xiaflex® on Dupuytren fibroblasts, offering a greater insight and a better understanding of its effect in DD.Farhatullah SyedAlexis N ThomasSubir SinghVenkatesh KolluruSusan G Emeigh HartArdeshir BayatPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 2, p e31430 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Farhatullah Syed Alexis N Thomas Subir Singh Venkatesh Kolluru Susan G Emeigh Hart Ardeshir Bayat In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.
description	Dupuytren's disease (DD) is a benign, fibroproliferative disease of the palmar fascia, with excessive extracellular matrix (ECM) deposition and over-production of cytokines and growth factors, resulting in digital fixed flexion contractures limiting hand function and patient quality of life. Surgical fasciectomy is the gold standard treatment but is invasive and has associated morbidity without limiting disease recurrence. Injectable Collagenase Clostridium histolyticum (CCH)--Xiaflex®--is a novel, nonsurgical option with clinically proven in vivo reduction of DD contractures but with limited in vitro data demonstrating its cellular and molecular effects. The aim of this study was to delineate the effects of CCH on primary fibroblasts isolated from DD and non-DD anatomical sites (using RTCA, LDH, WST-1, FACS, qRT-PCR, ELISA and In-Cell Quantitative Western Blotting) to compare the efficacy of varying concentrations of Xiaflex® against a reagent grade Collagenase, Collagenase A. Results demonstrated that DD nodule and cord fibroblasts had greater proliferation than those from fat and skin. Xiaflex® exposure resulted in dose- and time-dependent inhibition of cellular spreading, attachment and proliferation, with cellular recovery after enzyme removal. Unlike Collagenase A, Xiaflex® did not cause apoptosis. Collagen expression patterns were significantly (p<0.05) different in DD fibroblasts across anatomical sites - the highest levels of collagen I and III were detected in DD nodule, with DD cord and fat fibroblasts demonstrating a smaller increase in both collagen expression relative to DD skin. Xiaflex® significantly (p<0.05) down-regulated ECM components, cytokines and growth factors in a dose-dependent manner. An in vitro scratch wound assay model demonstrated that, at low concentrations, Xiaflex® enabled a faster fibroblast reparatory migration into the wound, whereas, at high concentrations, this process was significantly (p<0.05) inhibited. This is the first report elucidating potential mechanisms of action of Xiaflex® on Dupuytren fibroblasts, offering a greater insight and a better understanding of its effect in DD.
format	article
author	Farhatullah Syed Alexis N Thomas Subir Singh Venkatesh Kolluru Susan G Emeigh Hart Ardeshir Bayat
author_facet	Farhatullah Syed Alexis N Thomas Subir Singh Venkatesh Kolluru Susan G Emeigh Hart Ardeshir Bayat
author_sort	Farhatullah Syed
title	In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.
title_short	In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.
title_full	In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.
title_fullStr	In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.
title_full_unstemmed	In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.
title_sort	in vitro study of novel collagenase (xiaflex®) on dupuytren's disease fibroblasts displays unique drug related properties.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/97f76caf62034bed873be8847ebc93aa
work_keys_str_mv	AT farhatullahsyed invitrostudyofnovelcollagenasexiaflexondupuytrensdiseasefibroblastsdisplaysuniquedrugrelatedproperties AT alexisnthomas invitrostudyofnovelcollagenasexiaflexondupuytrensdiseasefibroblastsdisplaysuniquedrugrelatedproperties AT subirsingh invitrostudyofnovelcollagenasexiaflexondupuytrensdiseasefibroblastsdisplaysuniquedrugrelatedproperties AT venkateshkolluru invitrostudyofnovelcollagenasexiaflexondupuytrensdiseasefibroblastsdisplaysuniquedrugrelatedproperties AT susangemeighhart invitrostudyofnovelcollagenasexiaflexondupuytrensdiseasefibroblastsdisplaysuniquedrugrelatedproperties AT ardeshirbayat invitrostudyofnovelcollagenasexiaflexondupuytrensdiseasefibroblastsdisplaysuniquedrugrelatedproperties
_version_	1718423425879375872

In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.

Ejemplares similares